EU-CLAMP
Clinical Application for Metabolic Profiling
| Coordinatore | Profil Institut fur Stoffwechselforschung GmbH
Organization address
address: Hellersbergstrasse 9 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 1˙186˙320 € |
| EC contributo | 759˙837 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2010-1 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-12-01 - 2012-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
Profil Institut fur Stoffwechselforschung GmbH
Organization address
address: Hellersbergstrasse 9 contact info |
DE (Neuss) | coordinator | 249˙724.00 |
| 2 |
BVT Technologies, a.s.
Organization address
address: Hudcova 78c contact info |
CZ (Brno) | participant | 160˙554.00 |
| 3 |
DATAMED SRL
Organization address
address: VIA PAPA GIOVANNI XXIII 45 contact info |
IT (RODANO (MI)) | participant | 149˙907.00 |
| 4 |
Probe Scientific Ltd
Organization address
address: Sir Williams Lyons Road contact info |
UK (Coventry) | participant | 130˙821.00 |
| 5 |
JOANNEUM RESEARCH FORSCHUNGSGESELLSCHAFT MBH
Organization address
address: LEONHARDSTRASSE 59 contact info |
AT (GRAZ) | participant | 24˙979.00 |
| 6 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 23˙760.00 |
| 7 |
Medizinische Universitaet Graz
Organization address
address: AUENBRUGGERPLATZ 2 contact info |
AT (GRAZ) | participant | 20˙092.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Europe faces a diabetes epidemic. More than 55 million people in Europe are currently diagnosed with diabetes and with an estimated 20% increase by 2030, the disease is certain to stay one of the most challenging health problems this century. Especially as diabetes no longer is a disease exclusively for adults, but affects children, young people and adults of all ages. Despite the high prevalence of diabetes, the choice of anti-diabetic drugs is still limited and two thirds of patients with diabetes do not achieve the recommended glycaemic target levels. For each new anti-diabetic drug, it is essential to investigate the metabolic effect over time. The glucose clamp technique is regarded as the gold standard to evaluate the effectiveness of new anti-diabetic drugs. There are however only a few centers with limited research capacities that have experience in using the clamp technique, because automated clamp devices are no longer commercially available and the existing techniques are confounded by a number of limitations. Increased clamp capacities are urgently needed for the development of new, more efficacious anti-diabetic drugs. Through the integration of newly emerging technologies proposed in part by the 4 participating SME organisations and with the outsourced research capacity of 3 of Europe’s leading RTD performers, the EU-CLAMP project aims to develop a new generation automated clamp device that will overcome the limitations of the existing devices by incorporating microdialysis technique for reliable continuous glucose monitoring without blood loss. The EU-CLAMP project will facilitate clamp testing in a more efficient and cost effective manner. In addition to the significant contribution that will be made to development of improved treatment options for diabetes, the project will provide a platform from which the competitiveness of the participating SMEs can be improved offering alignment to the needs of their long term business strategies.'
Altri progetti dello stesso programma (FP7-SME)
ECOVARN (2010)
"Development of a wearable, functional, regulation-compliant Water-borne Wood Coating"
Read More